clinical trial · NCT07525544
A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants
ViiV Healthcare·phase1·recruiting·n = 214
HIV InfectionsVH4770359PlaceboMidazolam
brief summary
VH4770359 (also known as GSK4770359) is an antiretroviral compound. This first-in-human study aims to evaluate the safety, tolerability, and pharmacokinetics (PK) of orally administered VH4770359 in healthy participants. The findings from this study will support the design of future clinical studies of VH4770359 in people living with HIV.
started
May 14, 2026
primary completion
May 5, 2027
completion
May 5, 2027
last updated
Jul 13, 2026
official title
A Multi-part, Phase 1, First-Time-in-Human Study to Investigate Safety, Tolerability, and PK of VH4770359 in Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol